Skip to content

Earnings call

Advanced Enzyme Technologies Q3 FY25 earnings call: Advanced Enzyme Technologies Limited's goal is for Nashik R&D to be 3x bigger than what it has in the first stage at present

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Goal is for Nashik R&D to be 3x bigger than what it has in the first stage at present. The company achieved a top line of Rs. 1,691 million in Quarter 3, with growth of 5% on a year-on-year basis and 16% on a sequential basis. The company said it was still the leading player in this segment, while noting it is difficult for a leading player to hold more than 90% of the market share. The company adds at least 5 to 6 molecules every year and will continue to add them and increase this pace as it moves on. The company said it gets some 3-4% every year from rupee depreciation benefits on its U.S. holdings.

The numbers management gave

Results

  • The company achieved a top line of Rs. 1,691 million in Quarter 3, with growth of 5% on a year-on-year basis and 16% on a sequential basis.
    Show source
    We achieved a top line of Rs. 1,691 million, growth of 5% on a year-on-year basis and 16% on a sequential basis in Quarter 3.
  • EBITDA stood at Rs. 553 million in Quarter 3, growing by 3% on a year-on-year basis and 30% on a sequential basis; EBITDA Margin stood at 33% and PAT margin stood at 23%.
    Show source
    Our EBITDA stood at Rs. 553 million, grew by 3% on a year-on-year basis and 30% on a sequential basis.
  • Revenue for Quarter 3 Financial Year ‘25, after excluding the around Rs. 80 million of incremental revenue recognition delayed in Quarter 2 Financial Year ‘25, would have been Rs. 1,610 million, compared with Rs. 1,540 million for Quarter 2 Financial Year ‘25, a quarter-on-quarter growth of about 5% instead of 16%, with gross margin remaining at 77% in both quarters.
    Show source
    Accordingly, the revenue for this Quarter 3 Financial Year ‘25, after giving this effect, would have been at Rs. 1,610 million and for Quarter 2 Financial Year ‘25 would have been Rs. 1,540 million, a growth of 70 million on quarter-on-quarter basis, about 5% instead of 16%, and the gross margin remain at 77% in the Quarter 3 Financial Year ‘25 equivalent to Quarter 2 Financial Year ‘25.
  • Human Nutrition contributed around 60% of Advanced Enzyme Technologies Limited's revenue in Quarter 3.
    Show source
    Talking about the Human Nutrition the Human Nutrition contributed around 60% in this quarter.
  • Human Nutrition constituted about 68% of Advanced Enzyme Technologies Limited's revenue in 9 months of Financial Year ‘24 and 64% in 9 months of the current financial year.
    Show source
    On year-to-date basis, Human Nutrition constituted about 68% of the revenue in 9 months of Financial Year ‘24, and for current financial year 9 months it is 64%.
  • Animal Nutrition contributed 12% of Advanced Enzyme Technologies Limited's revenue in Quarter 3, and the segment grew by 22% on a year-on-year basis and 9% on a sequential basis.
    Show source
    This segment grew by 22% on year-on-year basis and 9% on sequential basis.
Show 13 more statements

Results

  • Animal Health Nutrition business increased by 12% year to date in Financial Year ‘25 and constituted about 12% of revenue, compared with 11% in year-to-date Financial Year ‘24.
    Show source
    Year-to-date Financial Year ‘25, Animal Health Nutrition witnessed an increase of 12% and constitute about 12% of the revenue as compared to 11% in year -to-date Financial Year ‘24.
  • Bioprocess contributed 19% of Advanced Enzyme Technologies Limited's revenue in Quarter 3 and grew by around 36% on a year-on-year basis and 91% on a sequential basis.
    Show source
    This segment outperformed during the quarter by around 36% on year-on-year basis and 91% on sequential basis.
  • Food business grew by 39% on a year-on-year basis and 130% on a sequential basis in Quarter 3, while its Non-Food business grew by 25% on a year-on-year basis and 4% on a quarter-on-quarter basis.
    Show source
    The Food business grew by 39% on year-on-year basis and 130% on sequential basis while Non- Food business reported growth of 25% on year-on-year basis and 4% on quarter-on-quarter basis.
  • Food business remained flat at Rs. 580 million year to date in Financial Year ‘25, constituting about 12% of total revenue.
    Show source
    Year-to-date performance of Food business remained flat at Rs. 580 million, constituting about 12% of the total revenue.
  • Specialized Manufacturing business contributed 9% of revenue in Quarter 3, grew by 49% year on year and 28% sequentially, and constituted about 8% of year-to-date revenue compared with 7% during the 9 months of Financial Year ‘24.
    Show source
    Specialized Manufacturing The Specialized Manufacturing business contributed 9% and grew by 49% on year-to-year basis and 28% on sequential basis and 27% of year-to-date and constituted about 8% of our total revenue as compared to 7% during the 9 months of Financial Year ‘24.
  • On a consolidated basis, Advanced Enzyme Technologies Limited's revenue increased by Rs. 230 million, or 16%, quarter on quarter in the 3rd Quarter of fiscal year 2025; EBITDA increased by Rs. 128 million, PBT increased by Rs. 108 million (about 26% growth, from Rs. 422 million to Rs. 530 million), and PAT increased by Rs. 55 million (16% growth, from Rs. 334 million to Rs. 389 million).
    Show source
    On the company's consolidated financials for the 3rd Quarter and nine months of fiscal year 2025, Q-on-Q basis the revenue is grew by Rs. 230 million, 16% of growth.
  • On a year-to-date basis in the nine months of fiscal year 2025, Advanced Enzyme Technologies Limited's revenue increased by Rs. 36 million, or 1%, from Rs. 4,661 million to Rs. 4,697 million; EBITDA increased by Rs. 3 million and profit before tax was slightly down.
    Show source
    On YTD basis, our revenue is increased by Rs. 36 million, 1% of increase from Rs. 4,661 million to Rs. 4,697 million.
  • Total expenditure on R&D on a standalone basis was Rs. 242 million, compared with Rs. 202 million.
    Show source
    So, total expenditure on AET standalone basis for R&D is Rs. 242 million as compared to Rs. 202 million.
  • Revenue, excluding the revenue recognition impact, would have been Rs. 161 crore for the current quarter compared with Rs. 154 crore for the last quarter, a growth of about 5%; revenue for the overall 9 months grew by 1%.
    Show source
    And then as far as the impact of, you know, the recognition of revenue , I think Mukund has already explained that in this quarter instead of Rs. 159 Crore, if we reduce that impact, it would have been Rs. 161 crore for this quarter and last quarter where it was Rs. 146 crore, it would have been Rs. 154 crore.
  • The company said detergent was negligible, while textiles and leather were doing well in its bioprocessing non-food segment.
    Show source
    Detergent is negligible as of now, but yes, textiles and leather, we are doing good in the bioprocessing non- food segment.
  • The company said its specialized manufacturing business was growing rapidly this year. Replaced by a later filing.
    Show source
    So, that business is growing rapidly.

Money and capital

  • The company said it gets some 3-4% every year from rupee depreciation benefits on its U.S. holdings.
    Show source
    I understand that, but apart from that, I think it's in safe hand, and we are getting a good return, and U.S. again you are getting some 3-4% every year that, you know, rupee depreciation benefits as well.
  • The company said it is getting a good return on money invested in the USA and may use money for an acquisition if an opportunity fits its strategic planning; it has also been giving an incremental dividend to investors.
    Show source
    And apart from that utilization, yes, at appropriate time, you know, whenever there are like ways to utilize like we have been giving an incremental dividend to our investors and apart from that , if there will be an opportunity of acquisition, which as we have mentioned earlier this fits to our strategic planning , then that money will be utilized .

What it expects ahead

What management expects

  • The company said there is a chance it can be a big beneficiary of the new political situation in the U.S. if the rules shake out right, while noting uncertainty about how tariffs and other major policy changes will change the landscape or the economy.
    Show source
    But there is a chance that we can be a big beneficiary here as well, if the rules shake out right.
  • The company said it expects only single-digit growth, not two-digit growth.
    Show source
    Beni Prasad Rauka: No, I think as far as, you know, guiding two-digit growth, we already mention that we will be having only single-digit growth.
  • The company said its main growth pillars would come from biocatalysts, the pharma area, human nutrition, food areas and animal feed areas.
    Show source
    The main growth pillars which is going to come is from the biocatalysts, from the pharma area and somewhat is from human nutrition, also like from the food areas and from the animal feed areas.
  • The company expected better growth in the industrial bioprocessing area.
    Show source
    And overall if we talk about the bioprocessing industrial area, we will have better growth.
  • The company said it was doing well in specialty business and expected to do well in the current year and next year. Replaced by a later filing.
    Show source
    Mukund Kabra: The way we see is like at least I can talk about the next one- or two-years short term, long-term we are always working, but the short-term scenario what I can see is on the specialty business we are doing good, we will be doing good this year as well as next year.

What it is building and selling

Projects and capacity

  • Goal is for Nashik R&D to be 3x bigger than what it has in the first stage at present.
    Show source
    In terms of Nashik R&D, when we talk about Nashik R&D, it will be 3x bigger than what we have in the first stage at present.
  • Capacity utilization was almost 55-60% in the quarter ended December 31, 2024; the company said it would expand when it reaches 80% of capacity levels.
    Show source
    Our utilization is almost like 55-60% still.
  • The company said it has already recruited a few people and is in the process of recruiting further for Nashik R&D.
    Show source
    There are few recruits we already did and we are in a process to recruit further.
  • The company established a separate independent laboratory named Starya Labs under its U.S. Subsidiary to focus on testing enzyme and probiotic products. Replaced by a later filing.

Demand and pricing

  • The company said it was still the leading player in this segment, while noting it is difficult for a leading player to hold more than 90% of the market share.
    Show source
    So, I won't go into more details about who is the player and what about the player and what is the impact, but I can always say that we are still the leading player into this segment.
  • The company said that growth in the nutraceutical market depends on how major brands’ research-driven products grow, and that this would lead to broader, more stable growth.
    Show source
    Now their growth depends on how this product grows, also impacts us of how our growth is going to happen.
Show 3 more statements

Segments

  • The company adds at least 5 to 6 molecules every year and will continue to add them and increase this pace as it moves on.
    Show source
    In terms of the addition of products, we already mentioned during our last few calls that every year we add at least 5 to 6 molecules, and we will continue to add and we will increase this pace as we move on.
  • The company provides enzymes for the detergent, textile, pulp, paper and leather industries in bioprocessed non-food.
    Show source
    So, as far as bioprocessed non-food is concerned, here we have like our enzymes for the detergent industry, textile, pulp, paper and leather industry.
  • Scitech Specialty Manufacturing, a subsidiary company of Advanced Enzyme Technologies Limited, conducts contract manufacturing activities on a P2P basis for human nutrition, animal nutrition and the nutraceutical segment.
    Show source
    And specialized manufacturing is something like, you know, we can also call it as a contract manufacturing where we do a lot of contract manufacturing activities on P2P basis in one of our subsidiary companies is Scitech Specialty Manufacturing.

Everything else said on the call

People and governance

  • The company is looking to expand its sales force quite a bit. Replaced by a later filing.
    Show source
    Vasant Rathi: We are in the process of adding lots more, to answer your question, Nitish, you are correct, we are looking to expanding the sales force quite a bit.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Bhavya Nahar: Hi, sir. I wanted to understand who will be heading the new facility in Nashik, given the departure of Dr. Anil Gupta, who I understand looked after the R&D function? And what is our product calendar looking like? Like are we focusing on repurposing our existing library of enzymes for new use cases or are we adding like more products there?

    Answer, mukund kabra

    Mukund Kabra: So, Dr. Gupta left long back. It's already like 3.5 years. And there are always the players who are there. R&D is in a good hand. There are many capable people who are handling those. In terms of Nashik R&D, when we talk about Nashik R&D, it will be 3x bigger than what we have in the first stage at present. That is our goal to begin with.

    Answer, mukund kabra

    There are few recruits we already did and we are in a process to recruit further. In terms of the addition of products, we already mentioned during our last few calls that every year we add at least 5 to 6 molecules, and we will continue to add and we will increase this pace as we move on.

  2. Question

    Bhavya Nahar: Okay. Sir, and regarding the vision of the company, as Rasika mentioned that the vision is to deepen footprint in nutraceutical, gut health, protein powder, and pet supplement. So, anything else? Because sir, generally, our aspirations are always on the right track, but something happens and we end up with anemic growth. So, for the next 5 to 7 years, exactly what's the growth plan?

    Answer, mukund kabra

    Mukund Kabra: So, Rasika was talking more about U.S. and U.S. business, how it is spanning it out. As you know and as we were talking about overall, we have like over 3 different segments, and we have already explained which are going to be the different growth areas into the different areas. Okay.

  3. Question

    Bhavya Nahar: And sir, last question. Sir, any plans to utilize the cash lik e 600 crores that we have on our books or any plans to, also any plans to bring the cash parked in the U.S. back to India?

    Answer, beni rauka

    Beni Prasad Rauka: So, as far as, you know, getting money back from U.S. is concerned, you know, we are getting a good return from that for whatever we have invested in USA. And apart from that utilization, yes, at appropriate time, you know, whenever there are like ways to utilize like we have been giving an incremental dividend to our investors and apart from that , if there will be an opportunity of acquisition, which as we have mentioned earlier this fits to our strategic planning , then that money will be utilized . Page 11 of 20 Advanced Enzyme Technologies Limited February 12, 2025 So, it is like, you know, utilized in a way which is giving us a return. Of course, in a way like, you know, if you look at the return from a business point of view, it is lower. I understand that, but apart from that, I think it's in safe hand, and we are getting a good return, and U.S. again you are getting some 3-4% every year that, you know, rupee depreciation benefits as well.

  4. Question

    Abhishek Navalgund: Yes, hi, thanks for the opportunity. The first question is again on the U.S. piece. So, you mentioned that the focus is to deepen the presence in the nutraceuticals. Some of the customers are also labeling and mentioning your name and stuff and also the focus areas were discussed. What we understand is clearly U.S. has been the key market for us since a very long period of time, but like the earlier participant also mentioned somehow the growth has been flattish. We are stuck at around 180-200 crore annual number. So, if you are actually seeing traction from the customers and, you know, higher visibility, what stops us for giving guidance from next one or two years' persp

    Answer, beni rauka

    Beni Prasad Rauka: So, regarding giving the guidance, definitely, you know, as such we have been talking time and again that, you know, we always aspire to give at least two digit of growth. But you know, sometimes what happens when you revisit your numbers, because last year we have seen the kind of some kind of growth is not there. So, in a way we call it a de-growth. So, we have to revisit our numbers. And that's the reason Mukund was saying that let me take some more time to churn out all the numbers, look at every customer, every product and see that where we can reach in the next year. So, that's the reason the guidance was probably Mukund of the opinion that we should not give the guidance in this particular quarter. Give us some more time so we will come out with the better guidance.

    Answer, beni rauka

    This will help you and everyone in the process.

  5. Question

    Abhishek Navalgund: But you are in a way saying that there are signs of recovery, right? So, you are indirectly saying that FY '26 is not going to be like '25 as far as the U.S. market is concerned.

    Answer, beni rauka

    Beni Prasad Rauka: Yes, So, Vasant sir is going to address.

    Answer, vasant rathi

    Vasant Rathi: Abhishek, Rasika was telling you before also is that we see a very broad, see, market is completely changing last two, three years. What is happening is it is more, this nutraceutical market is more of a research-driven products which are well proven technically and has a data supporting it. And most of the companies now are preferring to put our labels or our names, proprietary names, registered trademark names on their product. Major brands are coming with it. Now their growth depends on how this product grows, also impacts us of how our growth is going to happen. But it will be broader range growth, more stable growth. Page 12 of 20 Advanced Enzyme Technologies Limited February 12, 2025 Second thing which is happening, which nobody can imagine right now, is what is going to be the impact of various different countries.

    Answer, vasant rathi

    Even in North America, for example, Canada and Mexico are going to be impacted with a straight duty or no duty or how is it going to work because these markets are also very equally coming to our sphere in U.S. markets. Okay. So, there are a lot of areas which are going to impact, and that's why we are looking at the wait and see attitude for next 2-3 months before we can come up with our numbers or give some kind of guidance. Overall, we see a very positive trend as far as our product penetration is concerned, new products development is concerned, various different research papers and products which we are coming up with. So, yes, we are looking at growth numbers will tell a little bit later.

  6. Question

    Abhishek Navalgund: The next question is have we added any new customers, let's say, in the last 3 to 6 months and in any particular region per se?

    Answer, vasant rathi

    Vasant Rathi: Actually yes, we have added a few new customers in the last 6 months and they are global also. The company, this market is becoming a global market. It is not a regional market anymore. There is an enormous impact of how these global companies are coming up with and they have muscle power of advertisements and investments. So, a lot of merger acquisitions are happening in this industry also.

  7. Question

    Abhishek Navalgund: Okay. And in the Asia segment, excluding India, are there any market share gains story or this is, I mean, we should not read too much into it as far as this quarter number is concerned?

    Answer, mukund kabra

    Mukund Kabra: I would say that we shouldn't read too much at this point of time because we cannot like really comment on quarter-on-quarter basis. As we move on, we will have more clarity. We should look more on a 9-month's number or a longer number.

  8. Question

    Abhishek Navalgund: Sue. And last question, on the cash, on the balance sheet, are you reconsidering the dividend payout policy or something or that is going to be the same?

    Answer, vasant rathi

    Vasant Rathi: The dividend policies, listen, for the last two years we are declaring special dividends , right? So, our Board of Directors always consider those issues from time to time and take appropriate decisions. We are very much committed to our investors and making sure that their investment is taken care of.

  9. Question

    Abhishek Navalgund: Sure. So, yes, I missed one more. So , the Nashik R&D is on track to commission by end of first half or the timeline is different?

    Answer, mukund kabra

    Mukund Kabra: I think we were talking about end of this year '25.

    Answer, vasant rathi

    Vasant Rathi: Not the financial year, but this year.

  10. Question

    Abhishek Navalgund: Sure. Thank you.

    Answer, mukund kabra

    Mukund Kabra: As we were saying, this is going to be one of the growth areas and probably the growth we will see in the coming financial year. You are talking about the molecules. We always work on a lot of different molecules. We do add one or two molecules each quarter roughly at this time. That is the pace at which we are going on. Some molecules maybe we may see the commercialization coming into the next year. Niharika: Okay.

    Answer, mukund kabra

    And my next question is about the Probiotics market. So, in the investor presentation, we can see that the market size is around $70 billion. Do we have any plans in place to tap this market? Say, for example, even if we have 0.1% of this market, that would be an increase of 500-600 crores in top line. So, I wanted to understand more about this market.

    Answer, vasant rathi

    Vasant Rathi: Niharika, you are very correct. So, Probiotic market is fastly expanding and we are very much looking into key probiotics, which are already we have several papers published on various different probiotics right now. A lot of patents have been filed also on the complete enzymes and probiotics together, and we are expecting some of the products to be approved by the various different regulatory agencies in various different markets. Niharika: Understood. So, any possible impact on top line and by when can we see the impact of probiotics on top line?

    Answer, vasant rathi

    Vasant Rathi: It is going to be an integrated part of it, some of it. We are not separating that as a separate category per se, but we are integrating it in the enzymes and Probiotics because all our markets are, it's not about one or second product or one product by itself, but in U.S. market we have an integrated market of enzymes and probiotics. Niharika: Understood, understood. So, one more question. So, any specific reason why we have mentioned in the last con call that there will be no growth in India sales in FY '25? I mean, is it an industry trend or something specific for advanced enzymes?

    Answer, mukund kabra

    Mukund Kabra: So, Niharika, depending on looking at all the numbers what we saw last year and when we were like recalculating, revisiting all the projections, we realized that probably this year there will not be any growth. We did add some customers, but at the same time, we did lose some of the market Page 14 of 20 Advanced Enzyme Technologies Limited February 12, 2025 share, particularly into the anti-inflammatory area and some of the other areas. And that is where this recalculation of all the numbers came in. Niharika: Okay, understood. And one last question. So, we see that the asset turn is hovering around less than 1. So, wanted to understand about capacity utilization levels like what is the current level and when do we expect asset turn to move above 1?

    Answer, mukund kabra

    Mukund Kabra: We still have still like lot of capacity. Our utilization is almost like 55-60% still. We are at the same level. We will wait and see when we need to expand. As we were saying earlier as well, whenever we reach to 80% of the capacity levels, we will go for the expansion. The capacity is a very funny area. Sometimes you are at 55-60% and then something good happens in the R&D and that also increases your capacity.

    Answer, mukund kabra

    So, we are in a space where 1 plus 1 is not 2 but 11, and that is where this capacity utilization is always an interesting phenomenon. Niharika: Okay, understood. That's it from my end. Thank you.

Show 14 more questions
  1. Question

    Nitish Rege: Hi, my question is to Rasika. So, you know, how does the management plan to solve for the growth issue? You know, are we looking to add more people on the sales side? Because we have done good on the R&D side, so is it more of a sales issue? Just trying to understand, you know, at our side, why can't we grow faster?

    Answer, rasika rathi

    Rasika Rathi: Yes, we are always looking to add on the sales side. That is the quickest way to move us forward. And as I mentioned, it is a very key task that we are approaching very aggressively.

  2. Question

    Nitish Rege: So, you know, because of the M&A activities which has happened in our industry Novo, Hansen, DSM-Firmenich, there will be a lot of talent available. So, do we have any plans to hire them as consultants on our sales site to expand, to grow our USA, Europe business and incentivize them on sales which will also mitigate rise, increase in fixed costs for us?

    Answer, rasika rathi

    Rasika Rathi: Absolutely we do. It's a very good opportunity right now to pick up good salespeople.

    Answer, mukund kabra

    Mukund Kabra: And Nitish, we are already contacting few of the people.

    Answer, vasant rathi

    Vasant Rathi: We are in the process of adding lots more, to answer your question, Nitish, you are correct, we are looking to expanding the sales force quite a bit.

  3. Question

    Nitish Rege: And on the point of entry into new market segments, so do you map yourself against like global peers like Novo, DSM? What are the gaps, you know, in our product portfolio where we are not present currently compared to them? And have you identified any such products which we plan to launch in the coming years? Page 15 of 20 Advanced Enzyme Technologies Limited February 12, 2025 Mukund Kabra: There are always few products which we do launch.

    Answer, mukund kabra

    We always look for our niche opportunities as well. And these are the strategies. The area where we can take on we always go and take on. This year also like we are adding couple of industrial area where we can take on Novozymes or other people. We are working on the trials. We got few initial successes. We will wait for the final outcomes.

  4. Question

    Nitish Rege: And just on the competition, so, you know, today we are facing a lot of competition in Serra. In future, there will be another product where we will face competition. So, you know, do we have any targets of, let's say, 5 to 7% of our top line should come from new product, new initiatives, anything in that line?

    Answer, mukund kabra

    Mukund Kabra: So, we are not like really focusing growth on the Serra. And we were talking from last few quarters that the pharma segment will have just a few growths. The main growth pillars which is going to come is from the biocatalysts, from the pharma area and somewhat is from human nutrition, also like from the food areas and from the animal feed areas.

  5. Question

    Nitish Rege: So, just on this new product, so how large can these new products be?

    Answer, vasant rathi

    Vasant Rathi: They will be on the all fronts like what Mukund has just mentioned and that's where you can see a somewhat positive trend right now, Nitish, you know, the percentage of our sales are increasing to bioprocessing, animal feed, food processing, and healthcare area which is right now we already discussed quite a bit about. So, those are the way the company will grow in this.

  6. Question

    Nitish Rege: Okay. And on our geographical growth, s o just wanted to understand why is the growth rate especially in the USA, has been so volatile. So, if you look at 1H , we have grown around 24% year-on-year and then Q3 we have seen a decline of around 10%. So, you know, first of all, any thoughts on why the volatility and then secondly , any way we can reduce this?

    Answer, vasant rathi

    Vasant Rathi: Two answers, Nitish. Keep in mind that our company is not from quarter-to-quarter. Should not be judged on the quarter-to-quarter basis which we are telling for last so many years everybody who can listen. Second part which you mentioned, it was Mr. Raukaji already explained that Rs. 80 million were not counted in the 2nd Quarter, which is counted in this quarter. So, you see that it was like Rs. 154 crore sale was in last quarter instead of Rs. 146 crore, if I am correct on these numbers. And this quarter is not 170 plus something, but it is 161 something.

    Answer, vasant rathi

    Vasant Rathi: So, these numbers, see how it balances because sometimes with the regulatory, whatever the regulations are, you have to readjust according to whatever the rules and regulations are.

  7. Question

    Nitish Rege: Understood. Just one suggestion from my side. If the family could be there on all calls and meet investors, that would be really helpful for us. And yes, thank you for being on call this time and we look forward to interacting with the family going ahead.

    Answer, vasant rathi

    Vasant Rathi: No, absolutely. There is as much as possible, we are always open and ready to discuss crystal clearly. Everybody is here at this time and they are joining all of us. Page 16 of 20 Advanced Enzyme Technologies Limited February 12, 2025 Rasika Rathi: Absolutely.

  8. Question

    Ravi Purohit: Yes, thanks for taking my question. Most of my questions have been answered. Just specifically on this, you know, the segment-wise numbers that we put out in our presentation, there has been significant growth in, let's say, industrial bioprocessing and specialized manufacturing. Can you just throw some additional light on what these segments are? Are these growth rates sustainable? Are there any one-offs here or do you envisage significant, you know, particularly on the industrial bioprocessing side, there has been a lot of discussions about industrial bioprocessing enzymes and especially your global peers have been discussing that a lot being a very, very large opportunity. A

    Answer, mukund kabra

    Mukund Kabra: The way we see is like at least I can talk about the next one- or two-years short term, long-term we are always working, but the short-term scenario what I can see is on the specialty business we are doing good, we will be doing good this year as well as next year. On the bioprocessing side, this year in the food, we will have just like somewhat more growth, not like significant one but going forward it should be a good growth. And overall if we talk about the bioprocessing industrial area, we will have better growth.

  9. Question

    Ravi Purohit: So, what areas do we address in the industrial side? In the non-food side, what industries do we cater to? And similarly in specialized manufacturing, what industries do we cater to? I mean, if you could quote some examples, it will be easier for us to appreciate and understand the kind of work that we are doing. And just specialized manufacturing or specialty product factory, you know, we are not able to kind of understand correlated to anything.

    Answer, beni rauka

    Beni Prasad Rauka: No, I will appreciate. So, as far as bioprocessed non-food is concerned, here we have like our enzymes for the detergent industry, textile, pulp, paper and leather industry. Detergent is negligible as of now, but yes, textiles and leather, we are doing good in the bioprocessing non- food segment. And specialized manufacturing is something like, you know, we can also call it as a contract manufacturing where we do a lot of contract manufacturing activities on P2P basis in one of our subsidiary companies is Scitech Specialty Manufacturing. So, there we do it for human nutrition, animal nutrition, and, you know, the nutraceutical segment. So, that business is growing rapidly. That's what we could see this year.

  10. Question

    Ravi Purohit: Okay. And sir, you know, there has been one of our competitors who has been asked to close down their plant, Krebs Biochem, which I think is also a competitor to us for Serratio. Is this Page 17 of 20 Advanced Enzyme Technologies Limited February 12, 2025 something kind of that helps us or how is the competitive dynamic in the industry? Are you the only two players or is there anybody else in the industry which has been? I believe in the last few calls, we mentioned that that particular segment for us has been under pressure in India.

    Answer, mukund kabra

    Mukund Kabra: Yes, there will be few small manufacturers here and there. Krebs is one of the significant players, even if not directly, indirectly. We will see. Time will tell. But if that happens, then it will be a positive development on our side.

  11. Question

    Ravi Purohit: Okay. And one question for Mr. Rathi or Rasika, if one of you all could give a sense of, for us, when we look at the presentation that has been put out every quarter, there are segments which we are highlighting addressable market for us, right? Given our size and the addressable market for the company, right? So, there is a big, big gap between the two, which effectively means there is significant headroom for growth for us, right? But whereas if you look at our performance over the last few years, given our size, we are relatively very, very small and the growth mostly has come from M&A. So, is there any impediment that you have faced in the last few years which has not allow

    Answer, vasant rathi

    Vasant Rathi: Ravi, let me… Mukund Kabra: Pradeep.

  12. Question

    Ravi Purohit: Ravi. Ravi Purohit, yes.

    Answer, vasant rathi

    Vasant Rathi: Ravi, there are a lot of changes happening in the market and in this industry in U.S. or North America per se. Regulatory are very strong right now and lot of acquisitions, merger and acquisitions are happening. A lot of small players or niche players have been acquired by the big companies. You know that that becomes very challenging to continue sometimes with those. Also the industry is now more technical as I mentioned before. More data is required and then that not only data is required but it requires published data to back up the claims. Okay.

    Answer, vasant rathi

    So, there are a lot of these changes are happening in the industry which we are rapidly addressing. That's why I said in the beginning that we are now continuously publishing the papers, doing the research studies, and validating all those data and claims, which companies are required for the marketing. Does that make sense to you?

  13. Question

    Ravi Purohit: Sure, sir. And just one more question, right? So, we have launched a lot of B2C products in the Indian market, right? I think we have mentioned in the past that we have certain products in probiotic area in the U.S., but we have also launched, I think verify if I am not wrong, in the domestic market, right? Now we have traditionally been a B2B company. We are not traditionally a B2C company, especially in India. So, would it make sense for us to tie up with Page 18 of 20 Advanced Enzyme Technologies Limited February 12, 2025 actually a large pharmaceutical company in India, who can actually help us distribute these products better than having to us to kind of spend all that mon

    Answer, vasant rathi

    Vasant Rathi: Ravi, I appreciate your sugg estions and ideas. You are absolutely correct, we are a B2B company. B2C is a very different market segment by itself. We have a limited goal and objectives, but yes, as and when we go to B2C, which we are, it will be always a distribution we have to find with the major companies who have a good network of distribution and sales. So , yes, we are working on all of these different angles.

  14. Question

    Ravi Purohit: Okay, thanks a lot, sir, and thank you for your feedback as the other participants. We really appreciate if both you and Rasika can be on all the calls. Just four times in a year, not too much from a shareholder's point of view. And it gives us a lot of confidence and a lot of help to kind of hear your thoughts, right? So, we would really appreciate it if both of you all could be there in all the calls, please.

    Answer, vasant rathi

    Vasant Rathi: No, Ravi, yes, thank you. These interactions really help management in so many different ways and even sometimes we are not there on the call. Every single thought of yours and everybody is always debated, considered and we try to execute the issues in a way and manner which makes sense to all management and the investors alike. So, we appreciate your thoughts on that and we will, as Rasika said, try to be more interactive as much as possible.

Questions about this call

When was the Advanced Enzyme Technologies Q3 FY25 earnings call transcript filed?
Advanced Enzyme Technologies filed the transcript with the exchange on 17 Feb 2025. This page is built from that transcript.
What does this page list?
34 statements from the transcript across 7 topics, 20 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 24 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Advanced Enzyme Technologies Q3 FY25 concall: Advanced Enzyme Technologies Limited's goal is for Nashik R&D to be 3x bigger than what it has in the first stage at present · DalalOS